Oncocyte (NASDAQ:IMDX) Trading 9.4% Higher – What’s Next?

Shares of Oncocyte Corp (NASDAQ:IMDX) shot up 9.4% on Friday . The company traded as high as $7.48 and last traded at $7.32. 61,495 shares were traded during mid-day trading, an increase of 113% from the average session volume of 28,887 shares. The stock had previously closed at $6.69.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncocyte in a research report on Monday, December 29th. Wall Street Zen raised shares of Oncocyte to a “hold” rating in a report on Saturday, November 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Oncocyte Stock Performance

The stock has a market capitalization of $209.79 million, a price-to-earnings ratio of -2.59 and a beta of 1.35. The company has a 50 day moving average of $6.30.

Oncocyte (NASDAQ:IMDX) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.34) earnings per share (EPS) for the quarter. The firm had revenue of $0.26 million for the quarter. Oncocyte had a negative return on equity of 983.30% and a negative net margin of 1,380.69%.

About Oncocyte

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.